

EMA/166242/2018 ENCePP Code of Conduct Revision 4

European Network of Centres for Pharmacoepidemiology and

Pharmacovigilance

## Declaration of compliance with the ENCePP Code of Conduct

The (primary) lead investigator and a person authorised to sign on behalf of the coordinating study entity hereby declare<sup>1</sup> for the purpose of conducting the study *<include here study name and identifier/registration no.>*: "Impact of EU label changes for systemic diclofenac products: post referral prescribing trends" EMA/2015/26/PH - Specific Contract No 01 to

Framework service contract

- to follow the rules and principles for the independent and transparent conduct of pharmacoepidemiological and pharmacovigilance studies of the current version of the ENCePP Code of Conduct<sup>2</sup>;
- to inform the ENCePP Secretariat, of any change or decision to change that constitutes a deviation from the provisions of this Code.

It is of note that the (primary) lead investigator and the person authorised to sign on behalf of the coordinating study entity may be identical.

Name of (primary) lead investigator: Professor Thomas M MacDonald

Date: 23/05/2018 (dd/mm/yyyy)

Stamp (if applicable) and signature:

In Malan

Name of the coordinating study entity: University of Dundee

Address:

Nethergate, Dundee, DD1 4HN

Name of person authorised to sign on behalf of the coordinating study entity [if different from (primary) lead investigator]: PROFESSOR JACOB GEORGE

Date: 23/05/2018 (dd/mm/yyyy)

Stamp (if applicable) and signature:

The (primary) lead investigator should also complete, sign and date the Checklist of the ENCePP Code of Conduct.

<sup>&</sup>lt;sup>1</sup> Complete the declaration on screen, then print and scan a signed and stamped (if applicable) copy.

<sup>&</sup>lt;sup>2</sup> Adopted Code and any revision thereof at the time of signature of the declaration.